CliffBio
biologic

Skyrizi

risankizumab-rzaa

Loss of exclusivitySeptember 2037projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameSkyrizi
Active ingredientrisankizumab-rzaa
Strength180MG/1.2ML (150MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2025
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Skyrizi patent cliff — loss of exclusivity September 2037 | CliffBio